Vogl S E, Zaravinos T, Kaplan B H
Cancer. 1980 Jan 1;45(1):11-5. doi: 10.1002/1097-0142(19800101)45:1<11::aid-cncr2820450104>3.0.co;2-e.
A two-hour program of hydration with 2 liters of 0.45% saline-5% dextrose and diuresis with furosemide and mannitol was employed to administer cis-diamminedichloroplatinum(II) on an outpatient basis; 760 courses were administered to 158 patients. The dose was 50 mg/M2 every three to four weeks, and was given in combination with other anti-neoplastic agents in all but two patients. Only eight patients (5.13%) ever became azotemic. Of these, only three ever had serum creatinine determinations greater than 2 mg/dI, and azotemia was reversible in two months in all but one. Risk of azotemia did not increase with increasing cumulative dose. There were two anaphylactoid reactions, one sudden death, and two cases of hearing loss. Nausea and vomiting were universal, and often severe. This program of hydration and diuresis allows convenient outpatient administration of this drug with minor risk of mild nephrotoxicity.
采用为期两小时的水化方案，即输注2升0.45%生理盐水-5%葡萄糖溶液，并使用呋塞米和甘露醇进行利尿，以便在门诊给予顺二氯二氨铂(II)；共对158例患者进行了760个疗程的治疗。剂量为每三至四周50mg/M²，除两名患者外，所有患者均与其他抗肿瘤药物联合使用。仅有8例患者（5.13%）出现氮质血症。其中，只有3例患者的血清肌酐测定值超过2mg/dI，除1例患者外，所有患者的氮质血症在两个月内均可逆转。氮质血症的风险并未随累积剂量的增加而增加。发生了2例类过敏反应、1例猝死和2例听力丧失。恶心和呕吐很常见，且往往很严重。这种水化和利尿方案便于在门诊给药，且轻度肾毒性风险较小。
